Abstract: Objective To investigate the clinical value of hyperthermic intraperitoneal chemoperfusion (HIPEC) in tumor recurrence after rupture and bleeding of hilar cholangiocarcinoma (HCCA).Methods A total of 84 patients with rupture and bleeding of HCCA admitted to our hospital from January 2017 to December 2018 were selected and randomly divided into experimental group and control group, with 42 cases in each. The experimental group underwent radical resection combined with HIPEC, and the control group underwent radical resection. The basic data, postoperative hospital stay, complications, tumor-free survival, and overall survival of the 2 groups were compared. Cox multivariate analysis was used to analyze independent risk factors for prognosis.Results There was no significant difference in the time of postoperative hospital stay, the incidence of seroperitoneum, or the incidence of pleural effusion between the 2 groups (P>0.05). The average tumor-free survival time of experimental group was significantly higher than that of control group (P<0.05). The 6-month, 12-month and 18-month tumor-free survival rate and overall survival rate of experimental group were significantly higher than those of control group (P<0.05). Cox regression model analysis indicated that histological classification and HIPEC were independent risk factors for postoperative tumor-free survival time and overall survival time (P<0.05).Conclusion In rupture and bleeding of HCCA, HIPEC combined with radical resection can reduce the risk of tumor recurrence, prolong the tumor-free survival period and improve the long-term prognosis under the premise of safety. It is worthy of clinical promotion.

Key words: Hyperthermic intraperitoneal chemoperfusion, Rupture and bleeding of hilar cholangiocarcinoma, Radical resection, Tumor recurrence